Weekly Digest - September 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - September 2024
7 Sep 2024: Antibody-Drug Conjugate I-DXd shows clinically meaningful response in patients with extensive-stage small cell lung cancer
- Ifinatamab deruxtecan (I-DXd) showed clinically meaningful responses in pretreated patients with extensive-stage small cell lung cancer (ES-SCLC) in an interim analysis of the Phase 2 IDeate-Lung01 study
- The Phase 2 study evaluated two doses of I-DXd (8 mg/kg and 12 mg/kg), with the 12 mg/kg dose showing approximately twice the confirmed objective response rate (ORR) compared to the 8 mg/kg dose
- I-DXd demonstrated a confirmed ORR of 54.8% in the 12 mg/kg cohort and 26.1% in the 8 mg/kg cohort, with median durations of response of 7.9 months and 4.2 months, respectively
- The 12 mg/kg dose of I-DXd, despite having a higher frequency of treatment-emergent adverse events, has been selected as the optimal dose for further studies due to its superior efficacy
